Folic Acid–Based Multivitamin Therapy to Prevent Stroke
2004; Lippincott Williams & Wilkins; Volume: 35; Issue: 8 Linguagem: Inglês
10.1161/01.str.0000135228.20619.ad
ISSN1524-4628
AutoresGraeme J. Hankey, John W. Eikelboom,
Tópico(s)Cerebrovascular and Carotid Artery Diseases
ResumoHomeStrokeVol. 35, No. 8Folic Acid–Based Multivitamin Therapy to Prevent Stroke Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBFolic Acid–Based Multivitamin Therapy to Prevent StrokeThe Jury Is Still Out Graeme J. Hankey, MD, FRCP, FRACP and John W. Eikelboom, MBBS, MSc, FRACP, FRCPA Graeme J. HankeyGraeme J. Hankey From the Stroke Unit (G.J.H.) and the Department of Haematology (J.W.E.), Royal Perth Hospital, Perth, Australia; and the School of Medicine and Pharmacology (G.J.H., J.W.E.), University of Western Australia, Crawley, Australia. and John W. EikelboomJohn W. Eikelboom From the Stroke Unit (G.J.H.) and the Department of Haematology (J.W.E.), Royal Perth Hospital, Perth, Australia; and the School of Medicine and Pharmacology (G.J.H., J.W.E.), University of Western Australia, Crawley, Australia. Originally published1 Jul 2004https://doi.org/10.1161/01.STR.0000135228.20619.adStroke. 2004;35:1995–1998Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 1, 2004: Previous Version 1 There is a large body of observational and laboratory evidence suggesting but not proving that increasing plasma concentrations of total homocysteine (tHcy) is a causal risk factor for atherothromboembolic ischemic stroke and other vascular events.1–9Recent publication of the results of the landmark Vitamins in Stroke Prevention (VISP) Trial is the first evidence from a large randomized controlled trial (RCT) of the effect of lowering tHcy via folic acid–based multiple B vitamin supplementation on the incidence of "hard" clinical events, such as recurrent stroke, in patients with recent ischemic stroke.10,11 In contrast to what was expected from the epidemiological evidence, the VISP Trial did not identify a significant treatment effect of lowering tHcy by vitamin therapy on recurrent stroke, coronary events, or death, despite confirming a consistent and graded association between baseline tHcy and vascular risk (particularly the probability of stroke over time).11 Recruiting primarily from North America, VISP enrolled 3680 recent (3 to 120 days) survivors of nondisabling, noncardiogenic, ischemic stroke with baseline tHcy above the 25th percentile of the North American stroke population into a double-blind, randomized comparison of high versus low doses of a combination of 12 different vitamins, including folic acid, vitamin B12, vitamin B6, and riboflavin, which are cofactors for enzymes responsible for metabolizing homocysteine.11 After 2 years of follow-up, there was no significant difference in the cumulative incidence of the primary outcome event of recurrent cerebral infarction: 8.4% of 1814 patients who were allocated to high-dose multivitamins [including 2.5 mg of folic acid, 0.4 mg of vitamin B12, and 25 mg of vitamin B6] versus 8.1% of 1835 patients allocated to low-dose multivitamins [including 0.02 mg of folic acid, 0.006 mg of vitamin B12, 0.2 mg of vitamin B6]; risk ratio [RR], 1.0; 95% CI, 0.8 to 1.3; P=0.80.11 There was a nonsignificant reduction in death (5.4% in the high-dose group versus 6.3% in the low- dose group; RR, 0.9, 95% CI, 0.7 to 1.1) and the combined outcome of any stroke, coronary heart disease, or death (16.7% in the high-dose group versus 17.2% in the low-dose group; RR, 1.0; 95% CI, 0.8 to 1.1).11Is the Homocysteine Hypothesis of Atherothrombosis Still Viable?The first issue the VISP Trial results may challenge is whether the "homocysteine hypothesis" of atherothrombotic vascular disease is valid and whether it is perhaps another example of "hype" generated by observational studies that have identified an association between a marker of risk (tHcy) and an increased incidence of vascular disease but have failed to adjust for residual confounding by unknown or unrecorded risk factors or markers of risk. Recent examples include reports from observational studies of significant associations between antioxidant nutrients and hormone replacement therapy and reduced vascular disease, which were later refuted by large RCTs of antioxidant and hormone replacement therapy, respectively.12,13We believe the homocysteine hypothesis of atherothrombotic vascular disease in general, and stroke in particular, remains viable. Two recent studies using different methods yield consistent results in support of the hypothesis.9,14 In the Health Professional Follow-Up Study, the risk of ischemic stroke among 43 732 healthy men followed for 14 years was 29% (95% CI, 4% to 48%) lower among men whose dietary intake of folate was in the highest quintile compared with the lowest quintile.14 Although men with higher folate intake exercised more, were more likely to take aspirin regularly, and were less likely to be overweight or current smokers, the association was not altered substantially after adjustment for these more healthy lifestyle factors.14 It is possible that other unmeasured and unknown risk factors were not adjusted for in this study. However, these results and those of other observational studies1–9 are consistent with those of a "randomized" trial of "nature."9 Among individuals with a mutation in the gene coding for methylene tetrahydrofolate reductase (MTHFR), in which cytosine is replaced by thymidine at base position 677 of the gene, affected individuals have reduced activity of the MTHFR gene, increased tHcy by ≈20%, and an increased risk of stroke and other major vascular events.8,9 The presence or absence of this mutation in the MTHFR gene in any individual is an example of "random" assignment (by nature [ie, by genotype]) to a higher or lower tHcy. The results suggest that higher tHcy is associated with a higher risk of stroke and other vascular events, with a similar magnitude of association to that observed in other observational studies. Because the respective studies were prone to different potential sources of bias, it is compelling to still suggest that increased tHcy may be a causal risk factor for stroke.9,14Are the VISP Trial Results a True or a False Negative?The second question is whether the results of VISP accurately reflect a true lack of effect of folic acid–based multivitamin therapy in preventing major vascular events (ie, a true negative) or whether they are a type-II error (ie, a false negative) resulting from lack of statistical power.We believe that VISP did not have the statistical power to reliably exclude a modest but clinically important effect of folic acid–based multivitamin therapy in reducing the risk of major vascular events and death by up to 20% and 30%, respectively.The VISP Trial was designed on the assumption that it would be possible to achieve and maintain a difference in tHcy between the high-dose and low-dose vitamin treatment groups of 4 to 6 μmol/L, and hence, a reduction in the cumulative incidence of recurrent stroke during 2 years from 12% to 8.4% (relative risk reduction 30%).10 However, in practice, the achieved absolute difference in mean tHcy was only 2 μmol/L (13 μmol/L in patients allocated low-dose vitamins versus 11 μmol/L in patients allocated high-dose vitamins).11 The (unexpectedly) small difference of 2 μmol/L in tHcy is likely to reflect the high prevalence of vitamin supplement use in the North American community and the widespread fortification of the grain supply and staple foods in North America with folate that coincided with the inception of the VISP Trial.11,15,16 The latter may have reduced the statistical power of VISP by as much as 75%.17 Furthermore, the vitamin regimen used in VISP may have contained too little vitamin B12 in the high-dose group and too much in the low-dose group (more than the recommended daily intake) because in the presence of folate repletion, blood concentrations of tHcy are highly dependent on vitamin B12.18 The lower-than-anticipated rates of recurrent stroke in both treatment groups and the short duration of follow-up (2 years) also limited the statistical power of the VISP Trial. As the VISP investigators state, to confirm a statistically significant reduction in all-cause mortality of 10% (the size of the nonstatistically significant reduction observed in the VISP Trial), a sample size of 20 000 patients would have been required.11 We believe this underlines the importance of rapid completion of the other ongoing trial of folic acid–based B multivitamin therapy in patients with recent stroke, the VITAmins TO Prevent Stroke (VITATOPS) trial, which has presently recruited >4000 patients from 70 centers in 19 countries of 5 continents, and aims to follow up ≥8000 randomized patients for a mean of ≥2.5 years.19The VITATOPS Trial has adopted a somewhat different approach to testing whether the homocysteine hypothesis can be translated into a useful therapeutic intervention (Table).10,11,19 It is recruiting from the full spectrum of survivors of recent transient ischemic attacks of the brain and eye and all-cause stroke and not applying any eligibility criterion regarding level or metabolism of homocysteine at baseline. Some of these patients have low baseline tHcy and are therefore likely to derive at best only a modest absolute benefit from homocysteine-lowering therapy. However, the sample size calculations are based on predicted frequencies of a cumulative end point of new stroke, myocardial infarction, or vascular death of 8% per year in the control group, which receives a placebo, and 6.4% in the group receiving the active combination of only 3 compounds: folate plus vitamin B6 plus vitamin B12.19 These more conservative predictions of relative risk reductions (a decrease of 15% in VITATOPS versus 30% in VISP) explain why VITATOPS needs to accrue at least double the number of primary outcome events as in VISP. Comparison of VITATOPS and VISP Study DesignsVITATOPSVISP*25th percentiles were ≥10.5 μmol/L at the beginning of the study (November 1997); ≥9.5 μmol/L after April 8, 1998; and ≥9.5 μmol/L for men and ≥8.5 μmol/L for women after May 5, 1999.†Both high- and low-dose multivitamin arms also included 5000 international units (IU) of vitamin A, 400 IU of vitamin D, 30 IU of vitamin E, 60 mg of vitamin C, 300 μg of biotin, 1.5 mg of thiamin, 20 mg of niacinamide, 10 mg of pantothenic acid, and 80 μg of vitamin K.‡Countries in which folic acid fortification of staple foods is mandatory.TIA indicates transient ischemic attack; MRS, modified Rankin score.No. of patients80003688Eligibility Ageany≥35 years Diagnosisany stroke or TIAnondisabling (MRS≤3), noncardiogenic ischemic stroke Timingwithin 7 monthswithin 120 days Homocysteinenot measured routinelytHcy above 25th percentile*Interventionmultivitamins vs placebohigh- vs low-dose multivitamins†Experimental arm Folic acid2.0 mg2.5 mg Vitamin B120.5 mg0.4 mg Vitamin B625 mg25 mg Riboflavin—1.7 mgControl arm Folic acid—0.02 mg Vitamin B12—0.006 mg Vitamin B6—0.2 mg Riboflavin—1.7 mgFollow-upmedian, 4 years (range, 1 to 7 years)2 yearsPrimary outcomenew stroke, myocardial infarction, or vascular deathnew (recurrent) cerebral infarctionProjected primary event rates8% per year in control group12% during 2 years in control group6.4% per year in treated group8.4% during 2 years in treated groupStatistical power15% relative risk reduction (80% power)30% relative risk reduction (80% power)Participating countries (No. of centers)Australia (14); Austria (1); Belgium (1); Brazil (1); Hong Kong (2); Italy (5); Malaysia (2); The Netherlands (2); New Zealand (5); Moldova (1); United States (5)‡; Pakistan (1); Philippines (7); Portugal (4); Republic of Georgia (1); Singapore (1); Sri Lanka (1); United Kingdom (9); Yugoslavia (2)Canada (5)‡; North America (44)‡; United Kingdom (1)We have considered carefully whether VITATOPS should proceed now that VISP has returned an "equivocal" result and believe there are several reasons why VITATOPS should continue.First, the lower extreme of the 95% CIs of the estimates of VISP for the major outcome events is consistent with high-dose multivitamin therapy, reducing the risk of recurrent ischemic stroke by ≤20% and death by ≤30%.11 Perhaps even greater risk reductions can be achieved with greater reductions in tHcy, as may be achieved in other populations in which food is not supplemented with folate. These are clinically important treatment effects that cannot afford to be missed because of a type-II error. Indeed, several smaller recent trials of folic acid–based multivitamin therapy have reported similar and statistically significant benefits in surrogate measures of vascular events20–24 and a reduction in clinical events.25,26Second, the VISP Trial has not revealed any evidence of harm from attempts to reduce tHcy. Although the most recent clinical trial has suggested accelerated rates of restenosis in patients receiving folate and vitamin B12 and vitamin B6 supplements compared with placebo after coronary revascularization,27 the totality of evidence indicates continuing uncertainty as to benefit and harm from vitamin supplements and a lack of conclusive proof as to either.Third, even if VISP had indicated significant benefits associated with vitamin use, it would still be important to complete VITATOPS as planned, as well as other large trials of homocysteine lowering in nonstroke patients1 because of the ever-present chance that a type-I error had occurred and the result was a "false positive."Finally, the VITATOPS Trial aims to complement the experience of VISP by refining precision of the estimates of vitamin therapy effects on preventing stroke and other major vascular events in the same type of patients included in VISP and VITATOPS, and to extend the experience of VISP by exploring the effect of vitamin therapy in a broader range of patients (eg, with all ranges of tHcy), countries (eg, in Europe, Asia, and Australasia), and outcomes (eg, dementia and depression), and over a longer period of follow-up, as well as compared with placebo (Table). The individual patient data will ultimately contribute to a systematic review by the Homocysteine Lowering Trialists Collaboration (Robert Clarke, Clinical Trials Service Unit, Oxford, UK).Implications for Researchers and CliniciansCurrently, increased tHcy remains to be proven as a causal risk factor for ischemic stroke, and folic acid–based multivitamin therapy remains to be proven as a safe and effective (or ineffective) treatment to reduce the risk of stroke. Because there is consistent evidence of a possible causal association between tHcy and stroke risk from different epidemiological studies that are prone to different sources of bias, and because the VISP Trial has not reliably excluded a modest but clinically important effect of vitamin therapy, more data are needed to refine the estimates of effectiveness and to provide placebo-controlled estimates of effectiveness in other populations with different prevalences of genetic and environmental factors that influence tHcy. While awaiting the results of ongoing trials of folic acid–based multivitamin therapy and meta-analyses of these trials, insufficient evidence exists to recommend routine screening and treatment of high tHcy with folic acid and other vitamins to prevent atherothrombotic vascular disease. However, some clinicians will undoubtedly continue this empirical practice in selected high-risk patients for whom the potential benefits are believed to outweigh the potential risks and costs.G.J.H. is the principal investigator of the VITATOPS Trial, and J.W.E. is a member of the Steering Committee of the VITATOPS Trial.Section Editor: Marc Fisher, MD, and Antoni Dávalos, MDFootnotesCorrespondence to Dr Graeme J. Hankey, Clinical Professor, VITATOPS Trial Office, Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington St, Perth, Australia 6001. E-mail [email protected] References 1 Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999; 354: 407–413.CrossrefMedlineGoogle Scholar2 Eikelboom JW, Lonn E, Genest J Jr, Hankey GJ, Yusuf S. Homocyst(e)ine and cardiovascular disease. A critical review of the epidemiological evidence. Ann Intern Med. 1999; 131: 363–375.CrossrefMedlineGoogle Scholar3 Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischaemic stroke due to large- and small-artery disease but not other etiological subtypes of ischemic stroke. Stroke. 2000; 31: 1069–1075.CrossrefMedlineGoogle Scholar4 Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002; 22: 6–13.CrossrefMedlineGoogle Scholar5 Ford ES, SJSmith, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002; 31: 59–70.CrossrefMedlineGoogle Scholar6 Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology. 2002; 59: 529–536.CrossrefMedlineGoogle Scholar7 The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288: 2015–2022.CrossrefMedlineGoogle Scholar8 Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288: 2023–2031.CrossrefMedlineGoogle Scholar9 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325: 1202–1208.CrossrefMedlineGoogle Scholar10 Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) Trial: rationale and design. Neuroepidemiology. 2001; 20: 16–25.CrossrefMedlineGoogle Scholar11 Toole JF, Malinow R, Chambless L, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang C-H, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291: 565–575.CrossrefMedlineGoogle Scholar12 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321–333.CrossrefMedlineGoogle Scholar13 Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2003; 139: 56–70.CrossrefMedlineGoogle Scholar14 He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004; 35: 169–174.LinkGoogle Scholar15 Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999; 340: 1449–1454.CrossrefMedlineGoogle Scholar16 Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998; 338: 1009–1015.CrossrefMedlineGoogle Scholar17 Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001; 135: 133–137.CrossrefMedlineGoogle Scholar18 Quinlivan EP, McPartlin J, McNulty H, Ward M, Strain JJ, Weir DG, Scott JM. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet. 2002; 359: 227–228.CrossrefMedlineGoogle Scholar19 The VITATOPS Trial Study Group. The VITATOPS (VITAmins To Prevent Stroke) Trial: rationale and design of an international, large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002; 13: 120–126.CrossrefMedlineGoogle Scholar20 Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, Banga JD, Rabelink TJ. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2000; 20: 185–188.CrossrefMedlineGoogle Scholar21 Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol. 1999; 34: 2002–2006.CrossrefMedlineGoogle Scholar22 Verhaar MC, Wever RM, Kastelein JJ, van Loon D, Milstien S, Koomans HA, Rabelink TJ. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation. 1999; 100: 335–338.CrossrefMedlineGoogle Scholar23 Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998; 351: 263.Google Scholar24 Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, van Campen CM, Visser FC, Jakobs CA, Bulterjis EJ, Rauwerda JA. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000; 355: 517–522.CrossrefMedlineGoogle Scholar25 Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001; 345: 1593–1600.CrossrefMedlineGoogle Scholar26 Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. JAMA. 2002; 288: 973–979.CrossrefMedlineGoogle Scholar27 Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004; 350: 2673–2681.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hultdin J, Van Guelpen B, Winkvist A, Hallmans G, Weinehall L, Stegmayr B and Nilsson T Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes – evidence for an association with hemorrhagic stroke, Clinical Chemistry and Laboratory Medicine, 10.1515/CCLM.2011.234, 49:9 Sánchez-Moreno C, Jiménez-Escrig A and Martín A (2009) Stroke: roles of B vitamins, homocysteine and antioxidants, Nutrition Research Reviews, 10.1017/S0954422409990023, 22:1, (49-67), Online publication date: 1-Jun-2009. Sacco S and Carolei A (2007) Homocysteine and leukoaraiosis: time for a clinical trial?, Neurological Sciences, 10.1007/s10072-007-0827-8, 28:5, (235-237), Online publication date: 1-Oct-2007. Hankey G (2006) Is plasma homocysteine a modifiable risk factor for stroke?, Nature Clinical Practice Neurology, 10.1038/ncpneuro0093, 2:1, (26-33), Online publication date: 1-Jan-2006. Sabet H and Pettigrew L (2005) Hyperhomocyst(e)inemia and Carotid Atherosclerosis Carotid Artery Stenosis, 10.1201/b14239-10, (159-173), Online publication date: 28-Jul-2005. Hankey G and Eikelboom J (2005) Homocysteine and stroke, The Lancet, 10.1016/S0140-6736(05)17751-4, 365:9455, (194-196), Online publication date: 1-Jan-2005. August 2004Vol 35, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/01.STR.0000135228.20619.adPMID: 15232122 Manuscript receivedMay 28, 2004Manuscript acceptedMay 28, 2004Originally publishedJuly 1, 2004 Keywordshomocysteinefolic acidclinical trialsstroke preventionvitamin B complexPDF download Advertisement
Referência(s)